Novavax lines up manufacturing for COVID-19 vaccine candidate

24 July 2020
lab_biotech_test_big-1

Production has begun on the first batch of Novavax’s (Nasdaq: NVAX) COVID-19 vaccine candidate, under an agreement with a subsidiary of Fujifilm Corp (TYO: 4901).

The Japanese conglomerate’s biotech contract development and manufacturing organization (CDMO), FUJIFILM Diosynth Biotechnologies (FDB), is utilizing a site in North Carolina, USA.

Maryland, USA-based Novavax has agreed terms with FDB for the manufacture of the bulk drug substance for NVX-CoV2373, which was created using the firm’s recombinant nanoparticle technology.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology